Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has filed a registration statement on Form S-1

Liquidia Technologies, Inc.  (“Liquidia”), a late-stage clinical biopharmaceutical company focused on improving the performance of medicine by precisely engineering drug particles, today announced the appointment of Jeri Thomas as Senior Vice President, Commercial. Ms.

RESEARCH TRIANGLE PARK, NC – May 24, 2017   Liquidia Technologies, Inc., today announced initial data from its LIQ865 internal clinical development program, which is a PRINT® formulation for the sustained-delivery of free base bupivacaine for post-surgical pain relief.